… Vinflunine is approved in Europe for second-line treatment of … Hepatic dysfunction or
obstructive liver disease increases … In a population pharmacokinetic study of ixabepilone as …

… Agency-approved treatment is vinflunine, which offers modest … In a phase 1 trial of pan-FGFR
(FGFR1-4) inhibitor erdafitinib … evaluated in an open-label, phase 2 study in M/UR UC pts …

… , vinorelbine and vinflunine represent a promising approach for cancer treatment, in spite of
… Clinical pharmacokinetics, after intravenous infusion injection into the bolus in continuous …

… The pharmacokinetic data of EV was derived from three Phase I studies and one Phase II
study. … Chemotherapy chosen by the investigator was docetaxel, paclitaxel, or vinflunine. The …

… , vinflunine is used in the treatment of bladder cancer. Vindesine is used mainly in the treatment
of … tolerability and favourable pharmacokinetic profile in patients with solid tumours [162]. …

… Phase II trial (JASINT1) enrolled 69 patients in the first line setting and evaluated use of
vinflunine in … had urothelial cell cancers, with up to 24% of patients having liver disease and in a …

… been administered to cancer patients in order to prevent and treat cancer as an alternative
… camptothecin have been tested clinically, while vinflunine ditartrate, anhydrovinblastine, NK-…

… disease was available prior to the approval of atezolizumab in May 2016. Outside the US,
vinflunine is approved as a second‐line treatment… median response duration of 7.4 months [4]. …

… advanced UC using nonimmunotherapy approaches (ie, lapatinib, sunitinib, and vinflunine)
did not show significantly improved OS, with only vinflunine showing a PFS benefit [63], [64], […

… study were to establish safety and tolerability, pharmacokinetics, and the recommended phase
… conventional chemotherapy (docetaxel, paclitaxel or vinflunine) began accruing in 2018 (…